Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

VAL-083 potential in deadly brain cancer
May 2015
SHARING OPTIONS:

VANCOUVER, British Columbia—DelMar Pharmaceuticals, which has its administrative office in Canada and research operations in Menlo Park, Calif., has seen in-vivo efficacy of its drug candidate VAL-083 in glioblastoma multiforme (GBM). The current frontline system therapy for this cancer type is Temodar (temozolomide), but O6-methylguanine-DNA-methyltransferase (MGMT), a DNA repair enzyme, often causes chemotherapy resistance. However, since VAL-083’s cytotoxic mechanism of action is unique from that of TMZ and has been shown to be resistant to MGMT, it could offer GBM patients a new option. VAL-083 is capable of inhibiting neurosphere formation and growth of brain tumor-initiating cells BT74, GBM4 and GBM8. So far, the compound has demonstrated a favorable safety profile, and is safe and well tolerated at the doses tested to date. DelMar is evaluating VAL-083 in a Phase 1/2 trial to determine the safety and tolerability of its modernized dosing regimen, and anti-tumor activity, in GBM patients who have failed temozolomide and bevacizumab therapy.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.